Annual Meeting Report, March 29th 2023 Click here for NZSA Assessment and Voting intentions Metric 2020 2021 2022 Change Operating Revenue $97.4m $108.6m $110.9m 2% Fair value adjustment $72.5m $392.5m -$56.7m n/a Total Income $176.1m $517.2m $73.3m -86% EBITDA $135.7m $472.8m -$6.5m n/a NPAT $113.4m $452.8m -$13.9m n/a EPS1 $0.224 $0.896 -$0.028 n/a Capitalisation $1,412m…
Read more
Annual Meeting Report, February 28th 2023 Click here for NZSA Assessment and Voting intentions Metric 2021 2022 (re-presented) 2023 Change Revenue $315.3m $327.9m $352.1m 7% Underwriting Profit $30.3m $22.5m $23.6m 5% NPAT2 $10.8m $19.3m $17.6m -6% EPS1 $0.027 $0.046 $0.047 2% PE Ratio 27 15 15 Capitalisation $286.7m $261.8m -9% Current Ratio 1.57 1.57 1.37…
Read more
Annual Meeting Report, February 23rd 2023 Click here for NZSA Assessment and Voting intentions Metric 2020 2021 2022 Change Revenue $100.6m $105.7m $126.3m 19% Operating Expense $93m $118.2m 27% EBITDA $12.1m $12.7m $8.1m -36% NPAT -$31.7m $3.2m -$3.3m n/a EPS1 -$0.321 $0.032 -$0.033 n/a PE Ratio n/a 54 n/a Current Ratio 1.28 1.53 1.56 2%…
Read more
First published in The Briefing (Feb 20th 2023) It’s been the beginning of redemption for Ryman Healthcare this week. Redemption is in the form of a long-expected capital raise, Ryman’s first since listing, with the aim of reducing it’s significant debt burden and strengthening the company’s balance sheet. We’re pleased to see that the company…
Read more
